Last Updated: September 20, 2026
CJC-1295 is a synthetic GHRH analog that binds pituitary GHRH receptors to stimulate growth hormone release, and its mechanism centers on receptor activation, cAMP signaling, and half-life extension through albumin binding. This guide from Canada BioGenix breaks down how that process works at the molecular level, what the DAC component changes, and why researchers pair it with compounds like ipamorelin.
Most summaries of the CJC-1295 mechanism stop at “it raises growth hormone” and skip the part that actually matters: the drug’s behavior depends almost entirely on whether the DAC group is present. That single structural addition reshapes pharmacokinetics, dosing intervals, and the shape of the GH pulse a researcher observes.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland’s somatotroph cells. It belongs to the growth hormone secretagogue family, meaning it acts on the GHRH receptor rather than on ghrelin receptors (which is where ipamorelin and similar compounds operate).
The molecule was engineered to resist enzymatic breakdown better than native GHRH, which has a half-life measured in minutes. The result is a peptide that produces a sustained, dose-dependent rise in GH and downstream IGF-1 serum levels.
Three structural modifications define the peptide:
The no-DAC version, often labeled CJC-1295 without DAC or mod GRF(1-29), retains the stability modifications but loses the albumin anchor. That distinction drives nearly every practical difference between the two.
Binding begins when the peptide docks with the GHRH receptor on pituitary somatotrophs, a class of Gs protein-coupled receptors. Once bound, the receptor undergoes a conformational shift that activates the associated Gs protein, which in turn triggers adenylate cyclase.
The downstream effect is a rise in intracellular cAMP. Elevated cAMP activates protein kinase A, which opens voltage-gated calcium channels and drives the release of stored growth hormone granules. This is the core of the CJC-1295 mechanism: it does not supply exogenous GH, it amplifies the pituitary’s own secretory capacity.
The Gs protein pathway works as a signal amplifier rather than a simple switch. Each receptor activation event produces a cascade of cAMP, meaning small receptor occupancy can generate a disproportionately large secretory response. Researchers studying the CJC-1295 mechanism of action often note that this amplification explains the dose-dependent response curve seen in GH pulse amplitude measurements.
The DAC group is what separates CJC-1295 from short-acting GHRH analogs, and understanding it requires looking at the chemistry rather than just the outcome. DAC stands for Drug Affinity Complex: a maleimidopropionic acid moiety attached to the peptide that reacts selectively with the free thiol on cysteine-34 of endogenous serum albumin. That reaction is a Michael addition, a covalent, essentially irreversible bond, not a reversible ionic interaction. Once formed, the peptide-albumin conjugate circulates as a single entity.
Albumin is the most abundant plasma protein and is cleared slowly, so the peptide inherits the carrier’s pharmacokinetic profile. Instead of being degraded within minutes by DPP-IV and renal filtration, the conjugated peptide remains in circulation and continues to occupy pituitary GHRH receptors. The practical outcome is half-life extension from minutes to a span measured in days, depending on the formulation studied. This is why CJC-1295 with DAC is typically discussed in the context of weekly or twice-weekly administration in research protocols, while the no-DAC version requires more frequent dosing.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Albumin binding | Covalent Michael addition at Cys-34 | None |
| Half-life | Extended, days-scale | Short, hours-scale |
| Clearance route | Albumin-mediated, slow | Renal and proteolytic, fast |
| GH pulse pattern | Sustained elevation | Discrete pulses |
| Dosing frequency | Less frequent | More frequent |
| Receptor occupancy | Continuous | Intermittent |
| Best suited for | Sustained GH/IGF-1 elevation studies | Pulsatile secretion studies |
The table captures the trade-off researchers weigh most often, but the mechanism behind each row matters more than the row itself. The no-DAC version, often labeled mod GRF(1-29), retains the D-Alanine substitution and C-terminal modifications that resist enzymatic breakdown, but without the albumin anchor it is cleared on a timescale closer to native GHRH. The DAC version’s covalent bond means the peptide is not simply “longer-acting”; it is pharmacologically a different molecule with a different exposure curve.
Sustained exposure is useful for studying IGF-1 serum levels over time. Pulsatile exposure is closer to the body’s natural rhythm. Neither is universally “better”, it depends on the question being asked.
Pairing CJC-1295 with ipamorelin is a common research design because the two act on different receptors. CJC-1295 targets the GHRH receptor; ipamorelin targets the ghrelin receptor. Activating both pathways simultaneously produces a larger GH pulse than either compound alone, a pattern researchers describe as synergy.
Growth hormone release is naturally pulsatile, governed by the interplay of GHRH and somatostatin (pubmed.ncbi.nlm.nih.gov). A compound that keeps the GHRH receptor continuously activated can flatten that natural rhythm. Researchers interested in pulsatile secretion often favor the no-DAC version or lower-frequency protocols precisely to preserve the pulse architecture.
The measurable downstream effects of CJC-1295 fall into two categories: increased GH pulse amplitude and elevated IGF-1. Growth hormone itself has a short circulating half-life, so most research protocols track IGF-1 as the more stable marker of activity. IGF-1 is produced largely in the liver in response to GH receptor activation, and it mediates many of the anabolic and metabolic effects attributed to growth hormone, including protein synthesis and aspects of metabolic regulation.
For researchers building protocols around these distinctions, the peptide handling and documentation resources at research peptide protocols and documentation cover the practical side of variant selection and batch verification.
Purity is the variable that most often undermines otherwise sound research. A peptide that is 85% pure contains 15% unknown material, and in a study measuring subtle hormonal changes, that contamination can distort results in ways that are difficult to trace.
Continuous receptor activation can lead to desensitization, where the receptor becomes less responsive over time. This is a known phenomenon with Gs-coupled receptors and a legitimate concern in long-duration studies. Researchers typically address it with cycling protocols: defined periods of exposure followed by washout intervals that allow receptor sensitivity to recover. The specific cycle length depends on the compound, the dose, and the endpoint being measured, so there is no single universal schedule.
The CJC-1295 mechanism of action comes down to three things: GHRH receptor binding, cAMP-driven GH release, and albumin binding that extends the peptide’s active window. Understanding which version you are working with, and why, determines everything from dosing frequency to the shape of the hormonal response you observe.
In research settings, the effects of CJC-1295 are measured through changes in GH pulse amplitude and IGF-1 serum levels, not subjective feelings. Because the DAC extends the half-life, a single dose can elevate GH for several days. Researchers typically monitor biomarkers over weeks to assess dose-dependent responses. Individual timing varies with dose, route, and model, so there is no universal onset window.
CJC-1295 with DAC has a half-life of approximately 6 to 8 days in preclinical models, while the non-DAC version lasts only minutes to hours. This difference stems from covalent binding to endogenous albumin, which protects the peptide from rapid degradation. The extended half-life allows less frequent administration in research protocols and supports sustained GHRH receptor activation.
Yes, CJC-1295 acts on pituitary somatotrophs by binding to GHRH receptors, triggering cAMP signaling and the release of growth hormone. This interaction mimics the body’s natural GHRH but with a longer duration. In laboratory studies, the result is an increase in GH pulse amplitude without disrupting other hormonal axes, though researchers should monitor for receptor desensitization with continuous exposure.
Traditional secretagogues like ipamorelin act on ghrelin receptors, while CJC-1295 targets GHRH receptors. The key difference is the DAC, which binds to albumin and extends the half-life from minutes to days. This allows CJC-1295 to produce sustained GH release rather than a brief pulse. Researchers often combine it with ipamorelin to study synergistic effects on GH pulse amplitude.
Choosing a research peptide supplier is really a question of whether you can trust the documentation behind the vial. Canada BioGenix supports researchers with premium-quality research compounds, carefully selected manufacturing partners, and batch-specific quality documentation, plus free shipping on orders over $250 and credit card payment for convenience. Get started with Canada BioGenix and build your next protocol on a supply chain you can verify.
